JUL 03, 2019 06:36 AM PDT

Common Anticonvulsant Drug May Counteract Inflammation

WRITTEN BY: Nouran Amin

Sepsis is a serious medical condition that results from inflammation in the body and can cause fatal multi-organ dysfunction. The inflammation is usually triggered from a chromosomal protein called high-mobility group box 1 (HMGB1) that is secreted from immune or dying cells. Current treatments methods to counteract the inflammation lacks efficacy however, a common anticonvulsant and vasodilating drug called papaverine, discovered recently by scientists through a computer software-based docking study, may provide a strong therapeutic method.

Learn more about sepsis:

"Our research group has been trying to identify compounds, preferably based on existing drugs, that block the binding of irritants to cellular receptors,” says senior researcher, Professor Sei-ichi Tanuma from Tokyo University of Science (TUS). “We want to find novel drugs to treat inflammation-based conditions.”

Supposedly, papeverine can effectively counteract the inflammation in septic conditions by inhibiting the binding of HMGB1 to its receptor—known as RAGE. Findings of the study published in Biochemical and Biophysical Research Communications describes a novel approach involving the utilization of a computer software program known as "COSMOS” to develop a small protein that mimics the RAGE-binding domain of HMGB1. Results indicated that the designed protein effectively mimicked the binding domain and "competitively inhibited" the HMGB1-RAGE interaction. Using data generated from the DrugBank Library, they concluded that papaverine was structurally similar to the protein they designed.

"This in silico drug design approach, to find novel effects of papaverine, is a unique strategy employed for the first time only by TUS researchers,” says Professor Tanuma.

Laboratory studies have shown that papaverine successfully reduced death rates among model mice.

"Drug repositioning using the in silico drug discovery approach used in our research can repurpose existing drugs into novel therapeutic agents. Also, because the cost of 'designing' a novel drug is saved, such approaches can also radically reduce the cost of medical treatment. The next step is to understand the degree to which papaverine blocks HMGB1-RAGE interaction in the human body. We are now trying to optimize the structure of papaverine to design a more 'effective' drug for the future."

Source: Science Daily

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUL 18, 2019
Health & Medicine
JUL 18, 2019
The Healthiest Gut Makes the Healthiest Mind
  In a study published in February in the journal, Nature researchers report more evidence that microbial diversity in the human digestive system and...
JUL 18, 2019
Microbiology
JUL 18, 2019
Disrupting tRNA in Bacteria - A Way to Fight Antibiotic Resistant Microbes
Antibiotic-resistant bacteria already cause the deaths of around 23,000 people every year, and that number is expected to rise dramatically....
JUL 18, 2019
Drug Discovery
JUL 18, 2019
Drug Compound May Treat Common Genetic Kidney Disease
Researchers from the University of Sheffield in collaboration with Glasgow-based biotech company Mironid, have developed a new class of drugs for treating ...
JUL 18, 2019
Cancer
JUL 18, 2019
Using VR to Design Medicine
Being able to visualize and precisely understand molecular shapes is a key factor in drug design. Over the years, to envision and better understand molecul...
JUL 18, 2019
Drug Discovery
JUL 18, 2019
Anticholinergic Drugs and Dementia?
A link between anticholinergic drug use and cognitive impairment was recently observed from observational studies on randomized clinical trials. Regenstrie...
JUL 18, 2019
Drug Discovery
JUL 18, 2019
The Composition of Cerebrospinal Fluid in MS patients Could Be The Key To Treatments That Halt Progression
The range of disability for individuals living with multiple sclerosis (MS) varies significantly depending on the relapsing/remitting form of the disease....
Loading Comments...